With obesity rate consistently increasing, a strong relationship between obesity and fatty liver disease has been discovered. More than 90% of bariatric surgery patients also have non-alcoholic fatty liver diseases (NAFLDs). NAFLD and non-alcoholic steatohepatitis (NASH), which are the hepatic manifestations of metabolic syndrome, can lead to liver carcinogenesis. Unfortunately, there is no effective medicine that can be used to treat NASH or liver cancer. Thus, it is critically important to understand the mechanism underlying the development of these diseases. Extensive evidence suggests that microRNA 22 (miR-22) can be a diagnostic marker for liver diseases as well as a treatment target. This review paper focuses on the roles of miR-22 in metabolism, steatosis, and liver carcinogenesis. Literature search is limited based on the publications included in the PubMed database in the recent 10 years.

Original languageEnglish
Pages (from-to)74-80
Number of pages7
JournalLiver Research
Issue number2
Publication statusPublished - Jun 2020


  • Cancer
  • Hepatitis
  • Liver
  • Metabolism
  • MicroRNA-22(miR-22)
  • Non-alcoholic steatohepatitis
  • Steatosis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'MiR-22 as a metabolic silencer and liver tumor suppressor'. Together they form a unique fingerprint.

Cite this